Several recent studies showed that “hot” tumors, specifically those with increased T-cell proportions and expressing PD1 and TIM3, were associated with an improved prognosis for DLBCL patients after rituximab-based chemotherapy, while “cold” DLBCL cases with a depleted TME were associated with significantly worse outcomes [39]. The gene discussed is HAVCR2; the disease is diffuse large B-cell lymphoma.